|Bid||134.90 x 50000|
|Ask||136.00 x 50000|
|Day's range||133.65 - 135.10|
|52-week range||90.00 - 145.00|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Jazz Pharmaceuticals (JAZZ) gets FDA approval for label expansion of its cancer drug, Vyxeos, in pediatric patients with newly-diagnosed therapy-related acute myeloid leukemia.
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BZUN, EQR, FRPT, JAZZ, and SPTN have been added to the Zacks Rank #5 (Strong Sell) List on March 23, 2021